| An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ... Cancer cell 30 (3), 485-498, 2016 | 176 | 2016 |
| SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors TA Ahmed, C Adamopoulos, Z Karoulia, X Wu, R Sachidanandam, ... Cell reports 26 (1), 65-78. e5, 2019 | 170 | 2019 |
| Personalized preclinical trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies C Krepler, M Xiao, K Sproesser, PA Brafford, B Shannan, M Beqiri, Q Liu, ... Clinical Cancer Research 22 (7), 1592-1602, 2016 | 129 | 2016 |
| Saquayamycins G–K, Cytotoxic Angucyclines from Streptomyces sp. Including Two Analogues Bearing the Aminosugar Rednose KA Shaaban, TA Ahmed, M Leggas, J Rohr Journal of natural products 75 (7), 1383-1392, 2012 | 42 | 2012 |
| Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders X Wu, X Yang, Y Xiong, R Li, T Ito, TA Ahmed, Z Karoulia, C Adamopoulos, ... Nature cancer 2 (4), 429-443, 2021 | 40 | 2021 |
| Pyramidamycins AD and 3-hydroxyquinoline-2-carboxamide; cytotoxic benzamides from Streptomyces sp. DGC1 KA Shaaban, MD Shepherd, TA Ahmed, SE Nybo, M Leggas, J Rohr The Journal of antibiotics 65 (12), 615-622, 2012 | 40 | 2012 |
| Exploiting allosteric properties of RAF and MEK inhibitors to target therapy-resistant tumors driven by oncogenic BRAF signaling C Adamopoulos, TA Ahmed, MR Tucker, PMU Ung, M Xiao, Z Karoulia, ... Cancer discovery 11 (7), 1716-1735, 2021 | 37 | 2021 |
| Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients TA Ahmed, J Hayslip, M Leggas Cancer chemotherapy and pharmacology 72, 1369-1374, 2013 | 22 | 2013 |
| Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition TA Ahmed, J Hayslip, M Leggas Leukemia research 38 (11), 1350-1357, 2014 | 18 | 2014 |
| Validated LC–MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application TA Ahmed, J Horn, J Hayslip, M Leggas Journal of Pharmaceutical Analysis 2 (6), 403-411, 2012 | 17 | 2012 |
| Compositions and methods for treating CDK4/6-mediated cancer J Jin, X Yang, J Liu, Y Xiong, P Poulikakos, Z Karoulia, X Wu, T Ahmed US Patent 11,541,051, 2023 | 15* | 2023 |
| Compositions and methods for treating cdk4/6-mediated cancer J Jin, X Yang, J Liu, Y Xiong, P Poulikakos, Z Karoulia, X Wu, T Ahmed US Patent App. 17/453,619, 2022 | 5 | 2022 |
| High dose Simvastatin as a potential anticancer therapy in leukemia patients T Ahmed | 3 | 2013 |
| Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders P Poulikakos, X Wu, X Yang, Y Xiong, T Ito, T Ahmed, Z Karoulia, ... European Journal of Cancer 138, S5, 2020 | 1 | 2020 |
| Abstract LB-119: SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors C Adamopoulos, TA Ahmed, Z Karoulia, X Wu, R Sachidanandam, ... Cancer Research 79 (13_Supplement), LB-119-LB-119, 2019 | 1 | 2019 |
| Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients T Ahmed, J Hayslip, M Leggas Cancer Research 72 (8_Supplement), 3778-3778, 2012 | 1 | 2012 |
| WJH KJ Dabos World 16 (2), 112-114, 2024 | | 2024 |
| Abstract LB083: BRAF dimer-selective inhibitors synergize with BRAF monomer-selective inhibitors to overcome adaptive resistance and retain therapeutic index C Adamopoulos, T Ahmed, PM Ung, M Xiao, S Aaronson, C Ang, ... Cancer Research 82 (12_Supplement), LB083-LB083, 2022 | | 2022 |
| Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6 X Wu, X Yang, Y Xiong, R Li, T Ito, T Ahmed, Z Karoulia, C Adamopoulos, ... Cancer Research 81 (13_Supplement), 41-41, 2021 | | 2021 |
| A strategy for effective targeting of oncogenic BRAF signaling with increased therapeutic index using conformation-selective RAF and MEK inhibitors C Adamopoulos, TA Ahmed, MR Tucker, PM Ung, M Xiao, Z Karoulia, ... Cancer Research 81 (13_Supplement), 78-78, 2021 | | 2021 |
